Early interferon therapy reduces secondary myelofibrosis risk in young ET and PV patients. Cytoreductive drugs do not lower thrombotic event risk in young patients. Elevated white blood cell counts ...

For most patients younger than age 60 with polycythemia vera (PV) who are not considered high risk, cytoreductive therapies are withheld despite being highly effective. PV causes an overproduction of ...

The FDA granted a first-ever approval of an interferon for the rare blood disorder polycythemia vera (PV), also making ropeginterferon alfa-2b-njft (Besremi) the first approved PV therapy that ...

VIENNA--(BUSINESS WIRE)--AOP Health announced the final results on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from its CONTINUATION-PV study in an oral presentation at the ...

panelist discusses how polycythemia vera (PV) treatment approaches include both therapeutic phlebotomy and medications like hydroxyurea or interferon to control blood counts, with treatment selection ...

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...

The FDA has approved Pharmaessentia Corp.'s Besremi (ropeginterferon alfa-2b) for the rare blood disorder polycythemia vera, the interferon offering an alternative to JAK inhibitor therapy. PV is a ...

PharmaEssentia recently launched the What Counts campaign for its polycythemia vera (PV) drug Besremi. What Counts focuses on ensuring patients are being treated for all the “counts” associated with ...